Obesity-related hypertension: Epidemiology, pathophysiology, treatments, and the contribution of perivascular adipose tissue

Annals of Medicine

Volumn 44, Issue SUPPL. 1, 2012, Pages

  Aghamohammadzadeh, Reza ^a,b   Heagerty, Anthony M ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

Adiponectin; bariatric surgery; hypertension; inflammation; obesity; oxidative stress; perivascular adipose tissue; sympathetic nervous system

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTIOXIDANT; VITAMIN D;

ADIPOSE TISSUE; ADRENERGIC SYSTEM; BARIATRIC SURGERY; BODY MASS; CARDIOVASCULAR RISK; DIET THERAPY; EPIDEMIC; EXERCISE; HUMAN; HYPERTENSION; INCIDENCE; INFLAMMATION; KIDNEY DENERVATION; LIFESTYLE MODIFICATION; NONHUMAN; OBESITY; OBESITY RELATED HYPERTENSION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; WEIGHT REDUCTION;

ADIPOSE TISSUE; BLOOD VESSELS; HUMANS; HYPERTENSION; INFLAMMATION; OBESITY; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RENIN-ANGIOTENSIN SYSTEM; SYMPATHETIC NERVOUS SYSTEM;

EID: 84862518232     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2012.663928     Document Type: Review

References (98)

1. WHO. Obesity and Overweight: Fact Sheet number 311. 2011 [updated 2011; cited]; Available from: http://www.who.int/mediacentre/factsheets/fs311/en/ index.html (accessed 8 November 2009).
2. The NHS Information Centre LS. Statistics on obesity, physical activity and diet: England, 2011. Available from: http://www.ic.nhs.uk/pubs/opad11. Publisher: The health and social care information centre. (accessed 24 February 2011).
3. CDC. U.S. Obesity Trends. 2011 [updated 2011; cited 18 August 2011]. Available from: http://www.cdc.gov/obesity/data/trends.html#State.
4. Emerging Risk Factors Collaboration;Wormser D, Kaptoge S, Di Angelantonio E, Wood AM, Pennells L, et al. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet. 2011;377:1085-95.
5. Cornier MA, Despres JP, Davis N, Grossniklaus DA, Klein S, Lamarche B, et al. Assessing adiposity: a scientific statement from the American Heart Association. Circulation. 2011;124:1996-2019.
6. CDC. Hypertension. 2011 [updated 2011; cited 18 August 2011]. Available from: http://www.cdc.gov/nchs/fastats/hyprtens.htm.
7. WHO. Blood pressure. 2011 [updated 2011; cited 17 July 2011]. Available from: http://www.who.int/gho/ncd/risk-factors/blood-pressure-prevalence/en/ index.html.
8. Henry SL, Barzel B, Wood-Bradley RJ, Burke SL, Head GA, Armitage JA. The developmental origins of obesityrelated hypertension. ClinExpPharmacol Physiol. 2011 Aug 1. [Epub ahead of print].
9. Kotchen TA. Obesity-related hypertension: epidemiology, pathophysiology, and clinical management. Am J Hypertens. 2010;23:1170-8.
10. Gosmanov AR, Smiley DD, Robalino G, Siquiera J, Khan B, Le NA, et al. Effects of oral and intravenous fat load on blood pressure, endothelial function, sympathetic activity, and oxidative stress in obese healthy subjects. Am J Physiol Endocrinol Metab. 2010;299:E953-8.
11. Dobrian AD, Schriver SD, Lynch T, Prewitt RL. Effect of salt on hypertension and oxidative stress in a rat model of diet-induced obesity. Am J Physiol Renal Physiol. 2003;285:F619-28. (Pubitemid 37140246)
12. Hall JE, da Silva AA, do Carmo JM, Dubinion J, Hamza S, Munusamy S, et al. Obesity-induced hypertension: role of sympathetic nervous system, leptin, and melanocortins. J Biol Chem. 2010;285:17271-6.
13. Hall JE, Brands MW, Henegar JR. Mechanisms of hypertension and kidney disease in obesity. Ann N Y Acad Sci. 1999;892:91-107.
14. Rumantir MS, Vaz M, Jennings GL, Collier G, Kaye DM, Seals DR, et al. Neural mechanisms in human obesityrelated hypertension. J Hypertens. 1999;17:1125-33. (Pubitemid 29389560)
15. Esler M, Straznicky N, Eikelis N, Masuo K, Lambert G, Lambert E. Mechanisms of sympathetic activation in obesityrelated hypertension. Hypertension. 2006;48:787-96. (Pubitemid 44610980)
16. Nagae A, Fujita M, Kawarazaki H, Matsui H, Ando K, Fujita T. Sympathoexcitation by oxidative stress in the brain mediates arterial pressure elevation in obesity-induced hypertension. Circulation. 2009;119:978-86.
17. Van Harmelen V, Ariapart P, Hoffstedt J, Lundkvist I, Bringman S, Arner P. Increased adipose angiotensinogen gene expression in human obesity. Obesity. 2000;8:337-41.
18. Engeli S, Negrel R, Sharma AM. Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension. 2000;35:1270-7. (Pubitemid 30413663)
19. Goodfriend TL, Calhoun DA. Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. Hypertension. 2004;43:518-24. (Pubitemid 38282420)
20. Goodfriend TL, Egan BM, Kelley DE. Aldosterone in obesity. Endocr Res. 1998;24:789-96. (Pubitemid 29016481)
21. Goodfriend TL, Kelley DE, GoodpasterBH, Winters SJ. Visceral obesity and insulin resistance are associated with plasma aldosterone levels in women. Obes Res. 1999;7:355-62. (Pubitemid 129710596)
22. Maron BA, Zhang YY, Handy DE, Beuve A, Tang SS, Loscalzo J, et al. Aldosterone increases oxidant stress to impair guanylyl cyclase activity by cysteinylthiol oxidation in vascular smooth muscle cells. J Biol Chem. 2009;284:7665-72.
23. Wang H, Shimosawa T, Matsui H, Kaneko T, Ogura S, Uetake Y, et al. Paradoxical mineralocorticoid receptor activation and left ventricular diastolic dysfunction under high oxidative stress conditions. J Hypertens. 2008;26:1453-62.
24. Leopold JA, Dam A, Maron BA, Scribner AW, Liao R, Handy DE, et al. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med. 2007;13:189-97.
25. Maron BA, Leopold JA. Aldosterone receptor antagonists: effective but often forgotten. Circulation. 2010;121:934-9.
26. de Paula RB, da Silva AA, Hall JE. Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration. Hypertension. 2004;43:41-7. (Pubitemid 38031909)
27. Rahmouni K, Barthelmebs M, Grima M, Imbs JL, De Jong W. Involvement of brain mineralocorticoid receptor in saltenhanced hypertension in spontaneously hypertensive rats. Hypertension. 2001;38:902-6. (Pubitemid 34258690)
28. DeFronzo RA, Cooke CR, Andres R, Faloona GR, Davis PJ. The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man. J Clin Invest. 1975;55:845-55.
29. Kotsis V, Stabouli S, Papakatsika S, Rizos Z, Parati G. Mechanisms of obesity-induced hypertension. Hypertens Res. 2010;33:386-93.
30. Zheng Y, Yamada H, Sakamoto K, Horita S, Kunimi M, Endo Y, et al. Roles of insulin receptor substrates in insulin-induced stimulation of renal proximal bicarbonate absorption. J Am SocNephrol. 2005;16:2288-95. (Pubitemid 41725046)
31. Safar ME, Czernichow S, Blacher J. Obesity, arterial stiffness, and cardiovascular risk. J Am SocNephrol. 2006;17(Suppl 2):S109-11.
32. Singhal A, Farooqi IS, Cole TJ, O' R ahilly S, Fewtrell M, Kattenhorn M, et al. Influence of leptin on arterial distensibility: a novel link between obesity and cardiovascular disease? Circulation. 2002;106:1919-24. (Pubitemid 35176295)
33. Westerbacka J, Vehkavaara S, Bergholm R, Wilkinson I, Cockcroft J, Yki-Jarvinen H. Marked resistance of the ability of insulin to decrease arterial stiffness characterizes human obesity. Diabetes. 1999;48:821-7. (Pubitemid 29153082)
34. YudkinJS, Eringa E, Stehouwer CD. "Vasocrine" signalling from perivascular fat: a mechanism linking insulin resistance to vascular disease. Lancet. 2005;365:1817-20. (Pubitemid 40744663)
35. Jin RC, Loscalzo J. Vascular nitric oxide: formation and function. J Blood Med. 2010;2010:147-62.
36. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med. 2000;342:1378-84. (Pubitemid 30262394)
37. Wolk R, Shamsuzzaman AS, Somers VK. Obesity, sleep apnea, and hypertension. Hypertension. 2003;42:1067-74. (Pubitemid 37549057)
38. Yang R, Sikka G, Larson J, Watts VL, Niu X, Ellis CL, et al. Restoring leptin signaling reduces hyperlipidemia and improves vascular stiffness induced by chronic intermittent hypoxia. Am J Physiol Heart Circ Physiol. 2011;300:H1467-76.
39. Dudenbostel T, Calhoun DA. Resistant hypertension, obstructive sleep apnoea and aldosterone. J Hum Hypertens. 2010 Jun 9. [Epub ahead of print].
40. Soltis EE, Cassis LA. Influence of perivascular adipose tissue on rat aortic smooth muscle responsiveness. ClinExpHypertens A. 1991;13:277-96.
41. Gao YJ, Lu C, Su LY, Sharma AM, Lee RM. Modulation of vascular function by perivascular adipose tissue: the role of endothelium and hydrogen peroxide. Br J Pharmacol. 2007;151:323-31. (Pubitemid 46842669)
42. Galvez-Prieto B, Bolbrinker J, Stucchi P, de Las Heras AI, Merino B, Arribas S, et al. Comparative expression analysis of the renin-angiotensin system components between white and brown perivascular adipose tissue. J Endocrinol. 2008;197:55-64. (Pubitemid 351566925)
43. Lu C, Su LY, Lee RM, Gao YJ. Alterations in perivascular adipose tissue structure and function in hypertension. Eur J Pharmacol. 2011;656:68-73.
44. Dubrovska G, Verlohren S, Luft FC, Gollasch M. Mechanisms of ADRF release from rat aortic adventitial adipose tissue. Am J Physiol Heart Circ Physiol. 2004;286:H1107-13. (Pubitemid 38248627)
45. Deng G, Long Y, Yu YR, Li MR. Adiponectin directly improves endothelial dysfunction in obese rats through the AMPK-eNOS Pathway. Int J Obes (Lond). 2010;34:165-71.
46. Yilmaz MI, Sonmez A, Caglar K, Celik T, Yenicesu M, Eyileten T, et al. Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. Nephrology (Carlton). 2007;12:147-53. (Pubitemid 46426854)
47. Fesus G, Dubrovska G, Gorzelniak K, Kluge R, Huang Y, Luft FC, et al. Adiponectin is a novel humoral vasodilator. Cardiovasc Res. 2007;75:719-27. (Pubitemid 47243720)
48. Greenstein AS, Khavandi K, Withers SB, Sonoyama K, Clancy O, Jeziorska M, et al. Local inflammation and hypoxia abolish the protective anticontractile properties of perivascular fat in obese patients. Circulation. 2009;119:1661-70.
49. Aghamohammadzadeh R, Withers SB, Lynch FM, Greenstein AS, Malik R, Heagerty AM. Perivascular adipose tissue from human systemic and coronary vessels: the emergence of a new pharmacotherapeutic target. Br J Pharmacol. 2012;165:670-82.
50. Lu C, Zhao AX, Gao YJ, Lee RM. Modulation of vein function by perivascular adipose tissue. Eur J Pharmacol. 2011;657:111-6.
51. Lee RM, Bader M, Alenina N, Santos RA, Gao YJ, Lu C. Mas receptors in modulating relaxation induced by perivascular adipose tissue. Life Sci. 2011;89:467-72.
52. Byku M, Macarthur H, Westfall TC. Inhibitory effects of angiotensin (1-7) on the nerve stimulation-induced release of norepinephrine and neuropeptide Y from the mesenteric arterial bed. Am J Physiol Heart Circ Physiol. 2010;298:H457-65.
53. Marques FD, Ferreira AJ, Sinisterra RD, Jacoby BA, Sousa FB, Caliari MV, et al. An oral formulation of angiotensin-(1-7) produces cardioprotective effects in infarcted and isoproterenol-treated rats. Hypertension. 2011;57:477-83.
54. Ribiere C, Jaubert AM, Gaudiot N, Sabourault D, Marcus ML, Boucher JL, et al. White adipose tissue nitric oxide synthase: a potential source for NO production. Biochem-Biophys Res Commun. 1996;222:706-12. (Pubitemid 26194816)
55. Gil-Ortega M, Stucchi P, Guzman-Ruiz R, Cano V, Arribas S, Gonzalez MC, et al. Adaptativenitric oxide overproduction in perivascular adipose tissue during early diet-induced obesity. Endocrinology. 2010;151:3299-306.
56. Ribiere C, Jaubert AM, Sabourault D, Lacasa D, Giudicelli Y. Insulin stimulates nitric oxide production in rat adipocytes. BiochemBiophys Res Commun. 2002;291:394-9. (Pubitemid 34694418)
57. Mehebik N, Jaubert AM, Sabourault D, Giudicelli Y, Ribiere C. Leptin-induced nitric oxide production in white adipocytes is mediated through PKA and MAP kinase activation. Am J Physiol Cell Physiol. 2005;289:C379-87. (Pubitemid 41008884)
58. Rahmouni K, Correia ML, Haynes WG, Mark AL. Obesityassociated hypertension: new insights into mechanisms. Hypertension. 2005;45:9-14. (Pubitemid 40066405)
59. Mark AL, Shaffer RA, Correia ML, Morgan DA, Sigmund CD, Haynes WG. Contrasting blood pressure effects of obesity in leptin-deficient ob/ob mice and agouti yellow obese mice. J Hypertens. 1999;17(Pt 2):1949-53. (Pubitemid 30345336)
60. da Silva AA, do Carmo J, Dubinion J, Hall JE. The role of the sympathetic nervous system in obesity-related hypertension. CurrHypertens Rep. 2009;11:206-11.
61. Schleifenbaum J, Kohn C, Voblova N, Dubrovska G, Zavarirskaya O, Gloe T, et al. Systemic peripheral artery relaxation by KCNQ channel openers and hydrogen sulfide. J Hypertens. 2010;28:1875-82.
62. Lee YC, Chang HH, Chiang CL, Liu CH, Yeh JI, Chen MF, et al. Role of perivascular adipose tissue-derived methyl palmitate in vascular tone regulation and pathogenesis of hypertension. Circulation. 2011;124:1160-71.
63. Withers BS, Agabiti-Rosei C, Linvingstone DM, Little MC, Aslam R, Malik RA, et al. Macrophage activation is responsible for loss f anticontractile function in inflamed perivascular fat. ArteriosclerThrombVasc Biol. 2011;31:908-13.
64. Fitzgibbons TP, Kogan S, Aouadi M, Hendricks GM, Straubhaar J, Czech MP. Similarity of mouse perivascular and brown adipose tissues and their resistance to diet-induced inflammation. Am J Physiol Heart Circ Physiol. 2011;301:H1425-37.
65. Guo C, Ricchiuti V, Lian BQ, Yao TM, Coutinho P, Romero JR, et al. Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation. 2008;117:2253-61.
66. Gao YJ, Takemori K, Su LY, An WS, Lu C, Sharma AM, et al. Perivascular adipose tissue promotes vasoconstriction: the role of superoxide anion. Cardiovasc Res. 2006;71:363-73.
67. Lu C, Su LY, Lee RM, Gao YJ. Mechanisms for perivascular adipose tissue-mediated potentiation of vascular contraction to perivascular neuronal stimulation: the role of adipocyte-derived angiotensin II. Eur J Pharmacol. 2011;634:107-12.
68. Kanda H, Tateya S, Tamori Y, Kotani K, Hiasa K, Kitazawa R, et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest. 2006;116:1494-505.
69. Kim CS, Park HS, Kawada T, Kim JH, Lim D, Hubbard NE, et al. Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters. Int J Obes. 2006;30:1347-55. (Pubitemid 44306516)
70. Sartipy P, Loskutoff DJ. Monocyte chemoattractant protein 1 in obesity and insulin resistance. ProcNatlAcadSci USA. 2003;100:7265-70. (Pubitemid 36706427)
71. Shah R, Hinkle CC, Ferguson JF, Mehta NN, Li M, Qu L, et al. Fractalkine is a novel human adipochemokine associated with type 2 diabetes. Diabetes. 2011;60:1512-8.
72. Sirois-Gagnon D, Chamberland A, Perron S, Brisson D, Gaudet D, Laprise C. Association of common polymorphisms in the fractalkine receptor (CX3CR1) with obesity. Obesity (Silver Spring). 2010;19:222-7.
73. Timofeeva AV, Goryunova LE, Khaspekov GL, Kovalevskii DA, Scamrov AV, Bulkina OS, et al. Altered gene expression pattern in peripheral blood leukocytes from patients with arterial hypertension. Ann N Y Acad Sci. 2006;1091:319-35. (Pubitemid 47092247)
74. Chatterjee TK, Stoll LL, Denning GM, Harrelson A, Blomkalns AL, Idelman G, et al. Proinflammatory phenotype of perivascular adipocytes: influence of high-fat feeding. Circ Res. 2009;104:541-9.
75. DorresteijnJA, Visseren FL, Spiering W. Mechanisms linking obesity to hypertension. Obes Rev. 2012;13:17-26.
76. Lee CM, Huxley RR, Wildman RP, Woodward M. Indices of abdominal obesity are better discriminators of cardiovascular risk factors than BMI: a meta-analysis. J ClinEpidemiol. 2008;61:646-53.
77. Reisin E, Abel R, Modan M, Silverberg DS, Eliahou HE, Modan B. Effect of weight loss without salt restriction on the reduction of blood pressure in overweight hypertensive patients. N Engl J Med. 1978;298:1-6. (Pubitemid 8256364)
78. Ahmadi N, Eshaghian S, Huizenga R, Sosnin K, Ebrahimi R, Siegel R. Effects of intense exercise and moderate caloric restriction on cardiovascular risk factors and inflammation. Am J Med. 2011;124:978-82.
79. Blumenthal JA, Sherwood A, Gullette ECD, Babyak M, Waugh R, Georgiades A, et al. Exercise and weight loss reduce blood pressure in men and women with mild hypertension: effects on cardiovascular, metabolic, and hemodynamic functioning. Arch Intern Med. 2000;160:1947-58. (Pubitemid 30437579)
80. Heneghan HM, Meron-Eldar S, Brethauer SA, Schauer PR, Young JB. Effect of bariatric surgery on cardiovascular risk profile. Am J Cardiol. 2011;108:1499-507.
81. Nicholas C, May R. HealthGrades Fifth Annual Bariatric Surgery Trends in American Hospitals Study; 2010 Contract No.: Document Number. Available from: http://www.healthgrades.com/media/DMS/pdf/HealthGradesBariatric- SurgeryTrendsStudy2010.pdf. Publisher: HealthGrades Inc. (accessed 8 September 2010).
82. Hofso D, Nordstrand N, Johnson LK, Karlsen TI, Hager H, Jenssen T, et al. Obesity-related cardiovascular risk factors after weight loss: a clinical trial comparing gastric bypass surgery and intensive lifestyle intervention. Eur J Endocrinol. 2010;163:735-45.
83. Frezza EE, Wei C, Wachtel MS. Is surgery the next answer to treat obesity-related hypertension? J ClinHypertens (Greenwich). 2009;11:284-8.
84. Butner KL, Nickols-Richardson SM, Clark SF, Ramp WK, Herbert WG. A review of weight loss following Roux-en-Y gastric bypass vs restrictive bariatric surgery: impact on adiponectin and insulin. Obes Surg.2010;20:559-68.
85. Compher C, Badellino KO. Obesity and inflammation: lessons from bariatric surgery. JPEN J Parenter Enteral Nutr. 2008;32:645-7.
86. Ibrahim MM. Subcutaneous and visceral adipose tissue: structural and functional differences. Obes Rev. 2009;11:11-18.
87. Forsythe LK, Wallace JM, Livingstone MB. Obesity and inflammation: the effects of weight loss. Nutr Res Rev. 2008;21:117-33.
88. Moschen AR, Molnar C, Geiger S, Graziadei I, Ebenbichler CF, Weiss H, et al. Anti-inflammatory effects of excessive weight loss: potent suppression of adipose interleukin 6 and tumour necrosis factor {alpha} expression. Gut.2010;59:1259-64.
89. Blackburn GL, Wollner SB, Jones DB. Bariatric surgery as treatment for type 2 diabetes. CurrDiab Rep. 2010;10:261-3.
90. Kassab S, Kato T, Wilkins FC, Chen R, Hall JE, Granger JP. Renal denervation attenuates the sodium retention and hypertension associated with obesity. Hypertension. 1995;25(Pt 2):893-7.
91. SymplicityHTN-2 Investigators; Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The SymplicityHTN-2 Trial): a randomised controlled trial. Lancet. 2010;376:1903-9.
92. The 1st renal denervation procedure to control hypertension conducted in the private sector. The Harley Street Clinic; 2010 [updated 2010; cited]. Available from: http://www.theharleystreetclinic.com/news/the-1st-renal- denervation-procedure-to-control-hypertension-conducted-in-theprivate- sector (accessed 20 November 2011).
93. Vaziri ND, Ni Z, Oveisi F, Trnavsky-Hobbs DL. Effect of antioxidant therapy on blood pressure and NO synthase expression in hypertensive rats. Hypertension. 2000;36:957-64.
94. Drummond GR, Selemidis S, Griendling KK, Sobey CG. Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat Rev Drug Discov. 2011;10:453-71.
95. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25- Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest. 2002;110:229-38. (Pubitemid 34787360)
96. Wong KE, Szeto FL, Zhang W, Ye H, Kong J, Zhang Z, et al. Involvement of the vitamin D receptor in energy metabolism: regulation of uncoupling proteins. Am J PhysiolEndocrinolMetab. 2009;296:E820-8.
97. Wong KE, Kong J, Zhang W, Szeto FL, Ye H, Deb DK, et al. Targeted expression of human vitamin D receptor in adipocytes decreases energy expenditure and induces obesity in mice. J Biol Chem. 2011;286:33804-10.
98. Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of vitamin D in obesity. Am J ClinNutr. 2000;72:690-3. (Pubitemid 30667088)